P1324: A RISK-BASED STRATEGY FOR THE USE OF LETERMOVIR IN CMV-POSITIVE RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

P1324: A RISK-BASED STRATEGY FOR THE USE OF LETERMOVIR IN CMV-POSITIVE RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

Bibliographic Details
Main Authors:	D. Beauvais, M. Sourisseau, H. Béhal, S. Alfandari, N. Simon, E. Faure, I. Yakoub-Agha
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000848160.85133.ee

Similar Items

Letermovir Rescue Therapy in Kidney Transplant Recipients with Refractory/Resistant CMV Disease
by: Ellen von Hoerschelmann, et al.
Published: (2023-12-01)

Use of Letermovir for CMV Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation: Review of the Literature and Single-Center Real-Life Experience
by: Jessica Gill, et al.
Published: (2023-04-01)

Combined Therapy with Intravenous Immunoglobulins, Letermovir and (Val-)Ganciclovir in Complicated Courses of CMV-Infection in Transplant Recipients
by: Veronica Di Cristanziano, et al.
Published: (2021-08-01)

Resistant CMV infection in a transplant patient. Letermovir and withdrawal of immunosuppression
by: María Crucio López, et al.
Published: (2023-09-01)

Letermovir Primary Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients: A Matched Cohort Study
by: Léna Royston, et al.
Published: (2021-04-01)

CD4+ T cells are the major predictor of HCMV control in allogeneic stem cell transplant recipients on letermovir prophylaxis
by: Chris David Lauruschkat, et al.
Published: (2023-05-01)

Real-Life Data on the Efficacy and Safety of Letermovir for Primary Prophylaxis of Cytomegalovirus in Allogeneic Hematopoietic Stem Cell Recipients: A Single-Center Analysis
by: Martyna Wlodarczyk, et al.
Published: (2024-03-01)

Letermovir Prophylaxis and Cytomegalovirus Reactivation in Adult Hematopoietic Cell Transplant Recipients with and without Acute Graft Versus Host Disease
by: Delaney Wolfe, et al.
Published: (2021-11-01)

Real-life experience in two cases of secondary prophylaxis with letermovir for CMV infection in solid organ transplantation
by: Ana-Belén Pérez, et al.
Published: (2023-12-01)

The Presence of a CMV Immunodominant Allele in the Recipient Is Associated With Increased Survival in CMV Positive Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation
by: Dolores Grosso, et al.
Published: (2019-09-01)

Correction: Immunologic monitoring of cytomegalovirus (CMV) enzyme-linked immune absorbent spot (ELISPOT) for controlling clinically significant CMV infection in pediatric allogeneic hematopoietic stem cell transplant recipients.
by: Euri Seo, et al.
Published: (2023-01-01)

Donor–Recipient Story in Allogeneic Hematopoietic Stem Cell Transplantation
by: Elena Kum, et al.
Published: (2021-01-01)

Risk factors of CMV replication after allogeneic hematopoietic stem cell transplantation in children and adolescents
by: S. N. Shiriaev, et al.
Published: (2014-09-01)

Risk factors of CMV replication after allogeneic hematopoietic stem cell transplantation in children and adolescents
by: S. N. Shiriaev, et al.
Published: (2014-09-01)

Efficacy and safety of letermovir prophylaxis for cytomegalovirus infection after hematopoietic stem cell transplantation
by: Wen-Wen Li, et al.
Published: (2024-01-01)

The Use of Letermovir for Ganci clovi r-Res istan t Cytomegalovirus in Kidney Transplant Recipients
by: Nikolina Bašić-Jukić, et al.
Published: (2022-07-01)

P1334: THE IMPACT OF IMMUNOSUPPRESSION ON RECONSTITUTION OF CMV-SPECIFIC T CELLS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
by: A. Dmitrova, et al.
Published: (2022-06-01)

Cytomegalovirus Infection after Allogeneic Hematopoietic Cell Transplantation under 100-Day Letermovir Prophylaxis: A Real-World 1-Year Follow-Up Study
by: Dukhee Nho, et al.
Published: (2023-09-01)

Elevated Galectin-3 Plasma Concentrations in Recipients of Allogeneic Hematopoietic Cell Transplantation
by: Zachariah DeFilipp, et al.
Published: (2019-08-01)

Nutritional modulation of the gut microbiome in allogeneic hematopoietic stem cell transplantation recipients
by: Edoardo Muratore, et al.
Published: (2022-10-01)

How Do Donor-recipient CMV Serostatus and Post-hematopoietic Stem Cell Transplantation CMV Reactivation Affect Outcomes in Acute Leukemia Patients?
by: Mohammad Vaezi, et al.
Published: (2016-10-01)

Fecal Microbiota Transplantation in Allogeneic Hematopoietic Stem Cell Transplantation Recipients: A Systematic Review
by: Andrea Pession, et al.
Published: (2021-02-01)

Mycophenolate mofetil increases the risk of diarrhea in allogeneic hematopoietic stem cell transplantation recipients
by: Liangmo Lin, et al.
Published: (2023-10-01)

Combined Analysis of Early CD4<sup>+</sup> T Cell Counts and CMV Serostatus May Improve CMV Risk Assessment after Allogeneic Hematopoietic Cell Transplantation
by: Saskia Leserer, et al.
Published: (2021-11-01)

Delayed NK Cell Reconstitution and Reduced NK Activity Increased the Risks of CMV Disease in Allogeneic-Hematopoietic Stem Cell Transplantation
by: Ki Hyun Park, et al.
Published: (2020-05-01)

Drug interactions of tacrolimus with letermovir and azole antifungals following hematopoietic stem cell transplantation: A retrospective observational analysis
by: Yuri Shinogi, et al.
Published: (2023-08-01)

Different recovery patterns of CMV-specific and WT1-specific T cells in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: Impact of CMV infection and leukemia relapse
by: Xiao-Hua Luo, et al.
Published: (2023-02-01)

Cytomegalovirus (CMV) immune monitoring with ELISPOT and QuantiFERON-CMV assay in seropositive kidney transplant recipients.
by: Hyeyoung Lee, et al.
Published: (2017-01-01)

Decoupling blood telomere length from age in recipients of allogeneic hematopoietic cell transplant in the BMT-CTN 1202
by: Tsung-Po Lai, et al.
Published: (2022-10-01)

Longitudinal Detection of Twenty DNA and RNA Viruses in Allogeneic Hematopoietic Stem Cell Transplant Recipients Plasma
by: Marie-Céline Zanella, et al.
Published: (2023-04-01)

Paired Donor and Recipient Immunophenotyping in Allogeneic Hematopoietic Stem Cell Transplantation: A Cellular Network Approach
by: Friedrich Wittenbecher, et al.
Published: (2022-05-01)

Evaluating the Impact of Post-Transplant Cyclophosphamide and Anti-Thymocyte Globulin on CMV Reactivation Following Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Literature Review
by: Jarosław Dybko, et al.
Published: (2023-12-01)

Corrigendum: Different recovery patterns of CMV-specific and WT1-specific T cells in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: impact of CMV infection and leukemia relapse
by: Xiao-Hua Luo, et al.
Published: (2023-05-01)

Intrathecal cytomegalovirus immunoglobulin for CMV encephalitis post allogeneic stem cell transplantation
by: Ian Pang, et al.
Published: (2022-01-01)

Utility of CMV-Specific Immune Monitoring for the Management of CMV in Solid Organ Transplant Recipients: A Clinical Update
by: Katya Prakash, et al.
Published: (2021-05-01)

Long-term CMV monitoring and chronic rejection in renal transplant recipients
by: Shoko Ishikawa, et al.
Published: (2023-06-01)

Prevention and management of CMV infection in pediatric solid organ transplant recipients
by: Shanthi S. Balani, et al.
Published: (2023-02-01)

Fecal microbiota transplantation in the treatment of astrovirus infection in a recipient of an allogeneic hematopoietic stem cell transplant: a clinical case
by: Julia A. Bespyatykh, et al.
Published: (2023-04-01)

Hepatic complications of allogeneic hematopoietic cell transplantation
by: Ramazan Idilman, et al.
Published: (2008-09-01)

Letermovir for Cytomegalovirus Prophylaxis in Lung Transplant Patients with Valganciclovir-Induced Leukopenia
by: Arindam Singha, et al.
Published: (2021-04-01)